Targeting the mucosal interface

for the treatment of genetic and acquired disorders

Introducing a new class of drugs that targets complex interactions at the surface of the cell and mucosal interface in the lungs and digestive tract. Our Glycomics Technology Platform produces drugs with the ability to suppress inflammation, reduce infection, and improve healing. See Pipeline

See our lead program focused on controlling bacterial dysbiosis and GI inflammation
Learn how our drugs work at the mucosal interface
Partner with us to develop breakthrough therapeutics

Synedgen uses the science of glycomics – the study of complex sugar structure and function – to discover and develop ultra-purified therapeutic polysaccharides that are soluble, active, and targeted in the human body.  These new molecular entities are designed to alter the progression of diseases that currently have limited treatment options, and improve the lives of patients.

Our unique, proprietary glycomics platform

The Synedgen glycomics development engine provides a clear competitive advantage. Our technology platform, based on powerful and validated science, creates limitless product opportunities at mucosal and dermal systems where pathogens, external contaminants and exposure disrupt natural innate immune defenses. The glycomics technologies show unprecedented safety profiles in preclinical studies. Synedgen glycomics mediate inflammation and control wound healing at the dermal and mucosal interfaces and target drug therapeutics that support follow-on, broader indications.

Synedgen innovates products and therapies and develops core indications available for purchase or out-licensing to advance specific indications through market and distribution.

Improving lives by changing the progression of disease

News

October 27, 2016

Synedgen Announces Presentation of Data at NACFC Demonstrating Prevention of Gastrointestinal Complications with Glycopolymer-Based Therapeutics in a Preclinical Model of Cystic Fibrosis
Read More

October 27, 2016

Synedgen Reports Promising Data Demonstrating Biofilm Disruption and Potentiation of Antibacterial Activity in Burkholderia Clinical Isolates Treated with Glycopolymer-based Therapeutics
Read More

April 28, 2016

Prisyna Secures $6M in Financing
Read More